Loading
Life sciences · Journal article
Annals of Clinical and Translational Neurology · August 6, 2026
Encouraging direction, but not yet definitive.
This propensity-matched retrospective cohort study of 610 adults with epilepsy, obesity, and type 2 diabetes found that GLP-1 receptor agonist initiation was not associated with worsening seizure control compared to standard care, and achieved clinically meaningful weight loss and glycaemic benefit. The study's observational design and inability to exclude smaller harmful effects on seizure control limit the strength of conclusions, but findings are reassuring for use of this class in this comorbid population.
Retrospective cohort study with 1:1 propensity score matching. Adults with comorbid epilepsy, type 2 diabetes, and obesity from the NIH All of Us Research Program database; propensity-matched cohort of 610 patients with well-balanced baseline characteristics.. Intervention: Initiation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Compared with: Standard care (matched controls not receiving GLP-1 RAs). n = 610.
GLP-1 RA initiation showed no increased seizure-related hospitalization or new ASM addition compared to standard care (HR 0.92, 95% CI 0.68–1.23; p = 0.57) GLP-1 RA users achieved mean adjusted weight loss of −5.73% (p = 0.001) at 12 months HbA1c reduction of −0.71% (p = 0.018) in GLP-1 RA group at 12 months
Study powered to detect hazard ratios ≥1.53 for seizure worsening; smaller harmful effects cannot be excluded. No data on adverse events, tolerability, dosing patterns, or reasons for discontinuation provided.
These findings provide reassurance that GLP-1 receptor agonists can be safely initiated in patients with epilepsy for metabolic management, even among those taking weight-gaining antiseizure medications. However, clinicians should recognize that this is observational evidence with inherent confounding, and larger prospective studies would strengthen confidence in seizure safety.
Retrospective cohort study with propensity matching showing GLP-1 RAs safe for seizure control and effective for weight loss in epilepsy patients, but limited by observational design and inability to detect smaller harmful effects.
As stated by the source record.
Quoted from the source exactly as published.
These findings provide reassurance that GLP-1 receptor agonists can be safely initiated in patients with epilepsy for metabolic management, even among those taking weight-gaining antiseizure medications. However, clinicians should recognize that this is observational evidence with inherent confounding, and larger prospective studies would strengthen confidence in seizure safety.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
OBJECTIVE: Managing obesity in patients with epilepsy is complicated by the weight-gaining properties of essential antiseizure medications (ASMs) such as valproate and pregabalin. We evaluated the safety and efficacy of initiating glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in this population. METHODS: We conducted a retrospective cohort study using the NIH All of Us Research Program database, identifying adults with comorbid epilepsy, type 2 diabetes, and obesity. New initiators of GLP-1 RAs were compared with matched controls using 1:1 propensity score matching that included baseline weight-gaining ASM use. The primary safety outcome was a composite of seizure-related hospitalization or new ASM addition. Secondary efficacy endpoints (weight and HbA1c change at 12 months) were stratified by concomitant weight-gaining ASM use. RESULTS: The propensity-matched cohort included 610 patients with well-balanced baseline characteristics. GLP-1 RA initiation was not associated with failure to control seizure compared with standard care (hazard ratio 0.92, 95% CI 0.68-1.23; p = 0.57); given the observed events, the study could detect a hazard ratio of 1.53 or greater. GLP-1 RA users achieved a mean adjusted weight loss of -5.73% (p = 0.001) and an HbA1c reduction of -0.71% (p = 0.018). Significant weight reduction was achieved even among patients concomitantly treated with weight-gaining ASMs (adjusted difference -4.15%, p = 0.003). INTERPRETATION: GLP-1 RAs showed no evidence of seizure worsening and remained effective for weight loss even among patients receiving weight-gaining ASMs, supporting their use for metabolic benefit in patients with epilepsy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.